Ovarian tumors: a case series from a tertiary care center

Authors

  • Jishana Hameed C. V. Department of Obstetrics and Gynecology, GMC, Nagpur, Maharashtra, India
  • Sayalee Chafale Department of Obstetrics and Gynecology, GMC, Nagpur, Maharashtra, India
  • Rujuta Fuke Department of Obstetrics and Gynecology, GMC, Nagpur, Maharashtra, India
  • Madhuri Patil Department of Obstetrics and Gynecology, GMC, Nagpur, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20253909

Keywords:

Ovarian tumors, Case series, High-grade serous carcinoma, Mucinous cystadenocarcinoma, Dysgerminoma

Abstract

Ovarian cancer is the third most common malignancy among women in India and accounts for approximately 6% of cancer-related deaths, with late-stage presentation being frequent due to vague and nonspecific symptoms. This case series describes twelve patients with ovarian neoplasms diagnosed over six months at a tertiary care center, highlighting the clinical diversity and age-related distribution of these tumors. Most cases were observed in postmenopausal women above 50 years of age, with histopathological types ranging from high-grade serous carcinoma and mucinous carcinoma to mucinous cystadenoma, granulosa cell tumor, dysgerminoma, and metastatic malignant melanoma. Clinical manifestations included abdominal pain, distension, ascites, respiratory difficulty, and in one case, incidental detection during infertility evaluation. Risk factors such as nulliparity, delayed childbearing, and family history were noted. Management strategies varied from surgical excision for benign lesions to cytoreductive surgery with adjuvant chemotherapy for malignant cases. This study underscores the heterogeneity of ovarian tumors and the critical importance of early recognition, accurate histopathological classification, and individualized treatment planning. Despite advances in surgical and chemotherapeutic modalities, prognosis in advanced disease remains poor, emphasizing the need for improved screening strategies, molecular research, and targeted therapies to enhance survival and quality of life.

Metrics

Metrics Loading ...

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221-7. DOI: https://doi.org/10.1002/cncr.22371

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc. 2006;296(2):185-92. DOI: https://doi.org/10.1001/jama.296.2.185

Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237-49. DOI: https://doi.org/10.1007/s00428-012-1203-5

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9-32. DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0084

Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol. 2013;122(2):225-32. DOI: https://doi.org/10.1097/AOG.0b013e31829ce7ec

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. DOI: https://doi.org/10.3322/caac.21763

Murthy NS, Shalini S, Suman G, Pruthvish S, Mathew A. Changing trends in incidence of ovarian cancer—the Indian scenario. Asian Pac J Cancer Prev. 2009;10(6):1025-30.

Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91(17):1459-67. DOI: https://doi.org/10.1093/jnci/91.17.1459

Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, et al. Identifying symptoms of ovarian cancer: A qualitative and quantitative study. Br J Obstet Gynecol. 2008;115(8):1008-14. DOI: https://doi.org/10.1111/j.1471-0528.2008.01772.x

Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016;186(4):733-47. DOI: https://doi.org/10.1016/j.ajpath.2015.11.011

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. J Natl Compr Canc Netw. 2021;19(2):191-226. DOI: https://doi.org/10.6004/jnccn.2021.0007

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53. DOI: https://doi.org/10.1056/NEJMoa0908806

Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23:20-6. DOI: https://doi.org/10.1093/annonc/mds223

Ueland FR. A perspective on ovarian cancer biomarkers: past, present and future. Int J Gynecol Cancer. 2011;21(5):800-6.

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416-28. DOI: https://doi.org/10.1056/NEJMoa1911361

Downloads

Published

2025-11-27

How to Cite

C. V., J. H., Chafale, S., Fuke, R., & Patil, M. (2025). Ovarian tumors: a case series from a tertiary care center. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 14(12), 4350–4356. https://doi.org/10.18203/2320-1770.ijrcog20253909

Issue

Section

Case Series